Treatment with valproic acid for myelofibrosis with myeloid metaplasia
โ Scribed by Yasuyuki Inoue; Takao Suzuki; Madoka Takimoto; Michiko Irei; Shinji Yoshioka; Yasushi Shibuya; Masayuki Kato; Mitsuru Koike; Masatomo Takahashi
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 91 KB
- Volume
- 84
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Approximately 30โ50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely defined by previous retrospective studies. The current prospective study addresses thi
Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32
## Abstract Valproic acid (VPA) has been used as an anticonvulsant for decades. Recently, it was demonstrated that VPA also acts as a histone deacetylase inhibitor and induces differentiation and apoptosis in a variety of malignant cells in vitro. The effect of VPA on tumor cells differs according